We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sangamo Announces Second Expansion of Research Collaboration with LifeScan
News

Sangamo Announces Second Expansion of Research Collaboration with LifeScan

Sangamo Announces Second Expansion of Research Collaboration with LifeScan
News

Sangamo Announces Second Expansion of Research Collaboration with LifeScan

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sangamo Announces Second Expansion of Research Collaboration with LifeScan "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sangamo BioSciences, Inc. has announced the second expansion of its research collaboration with LifeScan, Inc. to use Sangamo's proprietary zinc finger DNA binding proteins (ZFPs) to develop therapeutic cell lines as a treatment for diabetes.

Under the agreement, Sangamo will receive expanded research funding from LifeScan through 2006.

"Our research collaboration with LifeScan illustrates the potential of our ZFP technology to play a key role in regenerative medicine approaches," said Edward Lanphier, Sangamo's president and chief executive officer.

"We can design and engineer ZFP transcription factors (ZFP TFs) that specifically regulate the expression of genes that LifeScan has identified as critical for the development of potential cell therapeutics for the treatment of diabetes.”

“Our initial collaboration has gone very well and we believe that LifeScan's decision to extend our agreement demonstrates their enthusiasm for our technology and its potential for developing novel therapeutics."

Advertisement